Sandoz Group AGMEX:SDZN 16 FCF Margin % is 10.52% as of Dec. 2025, which is 168% above its 10-year median of 3.92. GuruFocus rates MEX:SDZN with a GF Score™ of 16/100. The stock has 6 warning signs investors should review. Among 958 Drug Manufacturers companies, Sandoz Group AG ranks better than 63.47% on this metric.
The historical rank and industry rank for Sandoz Group AG's FCF Margin % or its related term are showing as below:
MEX:SDZN'
s FCF Margin % Range Over the Past 10 Years
Min: -2.64 Med: 3.92 Max: 8.55
Current: 7.17
During the past 4 years, the highest FCF Margin % of Sandoz Group AG was 8.55%. The lowest was -2.64%. And the median was 3.92%.
MEX:SDZN's FCF Margin % is ranked better than 63.47% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs MEX:SDZN: 7.17
Sandoz Group AG FCF Margin % Related Terms
Sandoz Group AG FCF Margin % Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:SDZN vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (MEX:SDZN) has a FCF Margin % of 10.52% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sandoz Group AG and its competitors. This is 168% above median its historical median of 3.92. According to the industry distribution chart, Sandoz Group AG ranks #350 out of 958 companies in the Drug Manufacturers industry, placing it in the top 36.5%.
Is Sandoz Group AG's FCF Margin % too high?
Sandoz Group AG's current FCF Margin % of 10.52% is 168% above median its 10-year median of 3.92. The Drug Manufacturers industry median FCF Margin % is 2.45. Sandoz Group AG's value of 10.52% is 330.3% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #350 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #350 out of 958 companies for FCF Margin %. This puts Sandoz Group AG in the upper half of its industry. The industry median FCF Margin % is 2.45. Sandoz Group AG's value of 10.52% is 330.3% above this benchmark. While the company's 10-year median is 3.92 vs. the industry median of 2.45, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current FCF Margin % of 10.52% is 330.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current FCF Margin % is 10.52%, which is 168% above median its own 10-year median of 3.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (MEX:SDZN) has a current FCF Margin % of 10.52%. The current FCF Margin % is 10.52%, which is 168% above median its 10-year median of 3.92 and 330.3% above the Drug Manufacturers industry median of 2.45. Sandoz Group AG's overall GF Score™ is 16/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sandoz Group AG (MEX:SDZN), the current FCF Margin % is 10.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
16GF Score
Get the complete analysis for MEX:SDZN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SDZN has been successfully added to your 